| Paris | |
| 387 | |
| Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocias insulin formulation portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry. | |
| Adocias clinical pipeline includes four novel insulin formulations for the treatment of diabetes: 1. Two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 in phase 2a and BioChaperone Lispro U200 in phase 1), these formulations have been licensed to Eli Lilly (signature of a partnership in December 2014). 2. A fast-acting formulation of human insulin (HinsBet U100) in phase 2a. 3. A combination of insulin glargine and a fast-acting insulin analog (BioChaperone Combo) in phase 2a. Besides Adocia developed a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer. This product is currently in phase 3 in India. |
|
| www.adocia.com | |
| ADOC:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 8 fois.